home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

353.93 +5.50 (+1.58%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

64 65 Next >

AbbVie's Strategic Move: ImmunoGen Acquisition Triggers Golden Cross, Yet Valuation Caution Remains ↗

January 11, 2024

AbbVie Inc (ABBV) stock is up 15% since acquiring ImmunoGen, but past Golden Cross rallies haven't sustained. With high valuation and competition, investors may want to wait for a pullback.

Via Benzinga

Dogs of the Dow: January’s Top 3 Picks to Buy for Big Gains ↗

January 10, 2024

Buying Dogs of the Dow stocks is an attractive strategy that involves buying stocks with high dividend yields that have often underperformed.

Via InvestorPlace

Topics Stocks

How Is The Market Feeling About Amgen? ↗

January 10, 2024

Via Benzinga

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

January 10, 2024

Via Investor Brand Network

Looking At Amgen's Recent Unusual Options Activity ↗

January 09, 2024

Via Benzinga

Investigating Amgen's Standing In Biotechnology Industry Compared To Competitors ↗

January 08, 2024

Via Benzinga

Looking At Amgen's Recent Unusual Options Activity ↗

January 05, 2024

Via Benzinga

Amgen Inc. (NASDAQ: AMGN) Records 52-Week High Tuesday Morning

January 02, 2024

Via Investor Brand Network

GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons

January 10, 2024

EQNX::TICKER_START (NASDAQ:LEXX),(NASDAQ:AMGN),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:WW) EQNX::TICKER_END

Via FinancialNewsMedia

3 health care stocks off to strong starts in 2024

January 10, 2024

With the bullish news flow lately, the market has taken a liking to health care stocks in recent weeks - including these three early 2024 gainers.

Via MarketBeat

Topics Artificial Intelligence

Is AI More Valuable In Advertising Than Healthcare? Jim Cramer Questions Wall Street's Preference ↗

January 10, 2024

Cramer shared his insights during his attendance at JPMorgan's healthcare conference,

Via Benzinga

Topics Artificial Intelligence

Amgen's Options: A Look at What the Big Money is Thinking ↗

December 28, 2023

Via Benzinga

Analyzing Amgen In Comparison To Competitors In Biotechnology Industry ↗

December 25, 2023

Via Benzinga

Is NASDAQ:AMGN a Good Fit for Dividend Investing? ↗

December 22, 2023

Why AMGEN INC (NASDAQ:AMGN) is a Top Pick for Dividend Investors.

Via Chartmill

Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

January 09, 2024

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END

Via FinancialNewsMedia

10 Health Care Stocks With Whale Alerts In Today's Session ↗

January 08, 2024

Via Benzinga

5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday ↗

January 08, 2024

The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.

Via Benzinga

Spotlight on Amgen: Analyzing the Surge in Options Activity ↗

December 21, 2023

Via Benzinga

Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

January 09, 2024

From FN Media Group LLC

Via GlobeNewswire

A Rough Start To 2024 What Might Be In Store For The Rest Of 2024? ↗

January 07, 2024

The market was weighed down by several negative factors that began before the bell even rang at Broad and Wall on the first trading day of this New Year.

Via Talk Markets

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

January 04, 2024

Via Benzinga

Will the Biotech sector sustain its momentum in 2024?

January 04, 2024

The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%.

Via MarketBeat

Topics ETFs

Revenge of the Boring Stocks! Dividends Are Sexy Again. ↗

January 03, 2024

Dividend stocks are leading the way in the first few days of 2024, indicating that boring is back! What that means for investors now.

Via InvestorPlace

Did Santa Claus Claus Leave Town A Day Early? ↗

January 02, 2024

With the exception of the Dow, stocks are down hard to begin the new calendar year.

Via Talk Markets

Topics Stocks

Dogs Of The Dow: Top 10 Highest Yielding Dow Jones Stocks, How To Get Dividends Of 3% to 7.4% In 2024 ↗

January 02, 2024

Twenty eight of the 30 Dow Jones Industrial Average components pay out dividends. A look at the top ten highest dividend yields.

Via Benzinga

Topics Stocks

3 Top ETFs I'm Planning to Buy Hand Over Fist in 2024, Despite All the Cheap Stocks on My Radar ↗

January 01, 2024

I'm adding some ETFs to my retirement portfolio in 2024; here are the three I'm starting with.

Via The Motley Fool

Topics ETFs Retirement

Amgen Stock Sees Relative Strength Rating Improve To 74 ↗

December 29, 2023

Amgen stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 69 to 74.

Via Investor's Business Daily

There Are Only 5 Dow Stocks I Wouldn't Buy in 2024 ↗

December 29, 2023

There's a lot to like about Apple, Microsoft, and most of the Dow Jones Industrial Average components in 2024.

Via The Motley Fool

Topics Stocks

Full Approval For Amgen's Flagship Cancer Drug Lumakras Pushed For Around Four Years ↗

December 26, 2023

Amgen Inc (NASDAQ: AMGN) announced that the FDA has reviewed the company's supplemental New Drug Application, seeking full approval of the KRAS-blocking drug

Via Benzinga

< Previous 1 2

...

26 27 28 29 30 31 32 33 34

...

64 65 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com